Skip to main content
OpenTrials
Completed

NCT Number: NCT05283876

Excimer Light in Psoriasis

The aim of this study is to determine the standard tissue levels of SP and its receptor in lesional skin of psoriasis patients in both developing and stationary stages before and after excimer light therapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kasr Al Ainy Faculty of medicine

Cairo, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type of Psoriasis: plaque psoriasis.
  • Less than 10% surface area.

Exclusion criteria

  • Erythrodermic psoriasis
  • Pustular psoriasis
  • Topical treatment for psoriasis for the past 2 weeks.
  • Systemic retinoids in the last 2 years.
  • Systemic treatments (including any drugs that affect SP level as Aprepitant) in the last 3 months.
  • Contraindications to excimer light therapy (history of skin malignancy or precancerous conditions like xeroderma pigmentosum or photosensitivity)

Treatment and study plan

Excimer light

Device

Excimer light sessions

Primary outcomes

  1. Excimer laser efficiency in active and stable psoriasis

    Time frame: through study completion, an average of 6 months

    Determine the clinical improvement using Local psoriasis severity index

  2. Excimer laser efficiency on neurogenic inflammation

    Time frame: through study completion, an average of 6 months

    level of affection of the neurogenic inflammation in psoriasis lesions after using Excimer light therapy. Determine substance P and its receptor levels before and after therapy.

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

Excimer Light Effect on Neurogenic Inflammation in Developing Versus Stationary Psoriasis Lesions

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Mar 17, 2022
Registry last updated
Feb 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.